Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.63 |
| ▸ | MAOA | P21397 | 9/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21052066 | 0.97 | MAOB (0.67) | MAOBMAOAHRH3FFAR4 | |
| SCHEMBL21098683 | 0.92 | MAOB (0.63) | MAOBMAOAHRH3 | |
| SCHEMBL13254657 | 0.86 | BRD4 (0.60) | MAOBMAOAHRH3ALOX15TSHR | |
| SCHEMBL21052060 | 0.86 | MAOB (0.60) | MAOBMAOAHRH3 | |
| SCHEMBL21052051 | 0.86 | MAOB (0.60) | MAOBMAOAHRH3 | |
| SCHEMBL21052076 | 0.84 | BRD4 (0.71) | MAOBMAOAHRH3 | |
| SCHEMBL7520647 | 0.83 | ALOX15 (0.68) | MAOBMAOAALOX15TSHRHSD17B10 | |
| SCHEMBL21098941 | 0.83 | MAOA (0.49) | MAOBMAOAALOX15TSHRHSD17B10 | |
| SCHEMBL17703887 | 0.80 | MAOB (0.67) | MAOBMAOAHRH3 | |
| SCHEMBL1377016 | 0.80 | MAOB (0.69) | MAOBMAOAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11576981-B2 | Acyl hydrazone linkers, methods and uses thereof | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2023-02-14 | — | — | US | disclosed |
| US-20200397916-A1 | ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2020-12-24 | — | — | US | disclosed |
| WO-2019109188-A1 | ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397916-A1 | ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | KAT7, AADAC, HDAC7 | MAOB 255/4885MAOA 264/4885HRH3 229/4885 |
| US-11576981-B2 | Acyl hydrazone linkers, methods and uses thereof | AADAC, HDAC8, KAT8 | MAOB 176/4885MAOA 220/4885HRH3 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.